Department of Anaesthesia and Intensive Care Medicine, Ystad Hospital, Ystad, Sweden.
Department of Clinical Sciences, Lund University, Lund, Sweden.
Scand J Clin Lab Invest. 2021 May;81(3):201-207. doi: 10.1080/00365513.2021.1884892. Epub 2021 Feb 19.
Plasma cystatin C and shrunken pore syndrome (SPS) are associated with increased mortality in older adults. The objective was to assess the association between these markers of kidney function at admission and mortality in hip fracture patients. Hip fracture patients presenting at Lund University Hospital were eligible for inclusion. Cox regression was used to assess association between plasma cystatin C, creatinine, cystatin C- or creatinine-based estimations of glomerular filtration rate (eGFR and eGFR), or SPS (defined as eGFR/eGFR < 0.7) and mortality during one year follow up. Improvement in discrimination relative to the Nottingham Hip fracture score was assessed by Receiver Operational Characteristics (ROC) analysis and calculation of Net Reclassification Index (NRI). 996 patients were included in the study. Cystatin C, creatinine, eGFR and eGFR were associated with one-year mortality in both unadjusted and adjusted analyses. The association with mortality was stronger for cystatin C and for eGFR than for creatinine and eGFR. Patients with SPS had doubled mortality compared with patients without SPS (43.7 and 20.2%, respectively, < .001). Hazard ratio for SPS in the adjusted analysis was 1.66 (95%CI; 1.16-2.39, = .006). None of the markers improved discrimination compared to the Nottingham Hip Fracture Score using ROC analysis whereas eGFR and eGFR improved NRI. Our conclusion is that plasma concentrations of creatinine or cystatin C, eGFR or eGFR or SPS at admission in hip fracture patients are associated with mortality when known risk factors are accounted for. Identification of high risk patients may be improved by eGFR or eGFR.
血浆半胱氨酸蛋白酶抑制剂 C 和小孔综合征(SPS)与老年人死亡率增加有关。目的是评估入院时这些肾功能标志物与髋部骨折患者死亡率之间的关系。在隆德大学医院就诊的髋部骨折患者符合入选条件。使用 Cox 回归评估血浆半胱氨酸蛋白酶抑制剂 C、肌酐、基于半胱氨酸蛋白酶抑制剂 C 或肌酐的肾小球滤过率(eGFR 和 eGFR)估计值或 SPS(定义为 eGFR/eGFR < 0.7)与一年随访期间死亡率之间的关系。通过接收者操作特征(ROC)分析和计算净重新分类指数(NRI)评估相对于诺丁汉髋部骨折评分的区分度改善。该研究共纳入 996 例患者。在未调整和调整分析中,半胱氨酸蛋白酶抑制剂 C、肌酐、eGFR 和 eGFR 均与一年死亡率相关。与死亡率的相关性在半胱氨酸蛋白酶抑制剂 C 和 eGFR 方面强于肌酐和 eGFR。与无 SPS 的患者相比,SPS 患者的死亡率增加了一倍(分别为 43.7%和 20.2%, < .001)。调整分析中 SPS 的风险比为 1.66(95%CI;1.16-2.39, = .006)。使用 ROC 分析,与诺丁汉髋部骨折评分相比,没有一种标志物能提高鉴别能力,而 eGFR 和 eGFR 提高了 NRI。我们的结论是,已知危险因素存在时,髋部骨折患者入院时的肌酐或半胱氨酸蛋白酶抑制剂 C、eGFR 或 eGFR 或 SPS 血浆浓度与死亡率相关。通过 eGFR 或 eGFR 可改善高危患者的识别。